Streetwise Reports' Article Archives — January 2019 back to current month (14)
Specialty Pharma 'Advances Pipeline' Ahead of Commercializing Lead Skin Therapy (01/30/2019)
LifeSci Capital reviewed the key takeaways from this Israeli firm's day-long research and development presentation.
Coverage Initiated on Developer of Therapies for Gastrointestinal Disorders (01/30/2019)
A ROTH Capital Partners report discussed this U.S.-based biopharma's two assets.
Anixa Doesn't Disappoint (01/29/2019)
Daniel Carlson of Tailwinds Research explains why he has designated this company his 2019 stock of the year.
Early Data for Biotech's Pain Drug Candidate 'Show Promise' (01/26/2019)
An H.C. Wainwright & Co. report reviewed Phase 1b data for this nonopioid medication being developed for patients with severe pain.
Commercial Launch Planned for Schizophrenia Drug (01/23/2019)
A drug used to treat schizophrenic patients will launch commercially in February in the U.S.
Analyst: Reaction to Trial Data 'Unwarranted' (01/23/2019)
An analyst's note reviewed the recently announced study results in pancreatic cancer as well as the subsequent decline in stock price.
Analyst Shares 'Revelations from a Pooled Safety Analysis' of Pain Drug (01/23/2019)
An H.C. Wainwright & Co. report discussed the analgesic's safety profile and how it compares to an on-the-market competitor.
Phase 2 Study Begins for German Biopharma's Cancer Drug Candidate (01/16/2019)
A LifeSci Capital report discussed two current trials in which this therapeutic is being evaluated.
Biotech's Flu Vaccine Shows 'Superiority to Market Leader' in Data (01/11/2019)
Study findings that differentiate this product from competitors were reviewed in a Ladenburg Thalmann research report.
Healthcare Solutions Provider to Acquire Medical Software Firm (01/10/2019)
The merger will allow the Canadian company to expand its online technology platform.
Target Raised on Nutraceutical Firm After It Inks 'Marquee Partnership' (01/09/2019)
The agreement terms and benefits of the partnership to this pharmaceutical company were relayed in an H.C. Wainwright & Co. report.
Biotech Enters License Agreement to Validate Biomarker as Alternative NASH Diagnostic (01/05/2019)
The background and justification for the deal was covered in an H.C. Wainwright & Co. report.
Potential Tenbagger Biopharma Displays 'Strong Start to New Year' (01/04/2019)
A ROTH Capital Partners report discussed the recent trial launch and provided upcoming catalysts for the stock.
Texas-Based Biopharma Gets PDUFA Date for Lead Orphan Disease Asset (01/02/2019)
An H.C. Wainwright & Co. report covered the potential timeline to market and subsequent estimated revenue for this therapeutic, which addresses a rare disorder in collagen production.
More Archives
2024Nov Oct Sep Aug Jul Jun May Apr Mar Feb Jan
2023Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2022Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2021Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
